Shanghai, China
Med-Fine Capital focuses on investment in healthcare and life sciences. The team has a deep background in healthcare industry and rich experience in venture capital. Headquartered in Shanghai, with business all over China, adhering to the concept of "focusing on healthcare and life sciences, giving full play to capital value and returning trust", the company is committed to becoming the most competitive professional healthcare venture capital firm in the world. Since 2016, Med-Fine Capital has invested in more than 40 companies, including Mabworks Biotech, Hanyu Medical, Lynk Pharma, Immvira, Zion Pharma, Amcare Lab, Chosen Medtech, Genomeprecision, Surgnova Healthcare, Weimi Bio-tech, SAFE Pharma, PharmaLegacy, and BioNova Pharma.
37
Total Investments
29
Portfolio Companies
-
Exits
2
Industries
General Information
Industries
Finance, Financial Services
Company Overview
Investment Criteria
Investment Thesis
•••••• •••••• ••••••
About Med-Fine Capital
Recent Investments (37)
View All| Company | Stage | Amount | Date |
|---|---|---|---|
| Series A | •••••• | Feb 2024 | |
| Seed Round | •••••• | Feb 2023 | |
| Series A - Med | •••••• | Jan 2023 | |
| Series A | •••••• | Sep 2022 | |
| Series A | •••••• | Jun 2022 | |
•••• ••••
|
Series B - Weimi Bio | •••••• | May 2022 |
|
•••• ••••
|
Series A - Med | •••••• | Apr 2022 |
|
•••• ••••
|
Seed Round | •••••• | Jan 2022 |
|
•••• ••••
|
Seed Round | •••••• | Nov 2021 |
|
•••• ••••
|
Series A - Med | •••••• | Oct 2021 |
All startup & investor data, one platform.
Filter investors by stage, sector, and geography. Compare portfolios side by side. Spot market signals before anyone else.
